Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Cisco Systems, Inc. (CSCO) -- Ignore unavailable to you. Want to Upgrade?

To: Eric who wrote (55967)	10/18/2001 1:43:11 PM
From: larry	Respond to of 77400

Eric, I think that pharma as a whole is a defense play in this environment. As a whole, the sector is a bit overvalued, especially if you believe that DOW is overvalued. You might pull out several winners out of the biotech area. So far the sector as whole is too expensive based on any valuation model. But if they can pull off several decent drugs, the payoff might be big. I cannot give you any names because the risk/reward ratio is also high. But one thing that I can be sure is that bioinformatics job market is still pretty hot. I can jump ship to get a 30-40% salary increase easily. Considering that my current salary is no that mean, it almost seems ridiculous that the pharma and big biotechs are willing to pay a high level bioinformatics scientist twice as much as they pay a senior level research sicentist. Bioinformatics and microarray techniques are sure to dramatically quicken the pace of drug discovery, but they are not gonna revolutionarize the industry. Sadly, lots of investors believe that they can, thus creating a big bubble in the biotech industry. larry